GuruFocus.com148d agoneutral
Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the BestGross margin above 82% during price cuts signals structural pricing power
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
27last 24h
848last 7d
142● bullish (7d)
89● bearish (7d)
214publishers
Simply Wall St.148d agoneutral
Is Pfizer (PFE) Pricing Its Long Term Cash Flow Potential Fairly TodayIf you are wondering whether Pfizer's current share price properly reflects its long term potential, the recent share performance gives you a useful starting point. At a last close of US$26.70, the stock has moved 0.1% over the past week, dipped 4.9% over the last 30 days, is up 6.0% year to date, and has risen 19.7% over the past year, with 3 year and 5 year returns of 16.3% and 13.4% declines respectively. Recent headlines around Pfizer have focused on its broader position in...
Insider Monkey149d agoneutral
Morgan Stanley Maintains Pfizer (PFE) at Equal Weight, Highlights Patent ConcernsPfizer Inc. (NYSE:PFE) is included among the 10 Innovative Dividend Stocks to Buy Right Now. On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on the stock. The firm said that Pfizer has reached a settlement with all three Vyndamax generic filers. The […]
Insider Monkey149d agoneutral
Pfizer (PFE) Among Best Medical Stocks Under $30 to Invest In?Pfizer Inc. (NYSE:PFE) is one of the 10 Best Medical Stocks to Buy Under $30. On April 20, Pfizer Inc. (NYSE:PFE) announced, together with Astellas Pharma Inc., that the US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for Priority Review. The application is for the use of PADCEV (enfortumab vedotin-ejfv) […]
Investor's Business Daily149d agobullish
Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%Alnylam stock popped Thursday on a solid first-quarter beat for its Pfizer-rivaling heart disease drug, Amvuttra.